---
title: Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as
  adjunct to intensive induction therapy and double-blinded intensive post-remission
  therapy with or without glasdegib in patients with newly diagnosed acute myeloid
  leukemia
date: '2024-02-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38385304/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240222170805&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Not ...
disable_comments: true
---
Not ...